Search Results for: 99

December 29, 2025 08:00 ET – EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive design to potentially optimize trial timelines and outcomes – – Theriva to schedule an End-of-Phase 2

November 12, 2025 08:00 ET – Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 – – Next generation oncolytic virus VCN-12 preclinical data presented at the 32nd Annual Congress European Society of Gene

October 16, 2025 08:11 ET ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of

October 06, 2025 08:00 ET – Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects – – Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors –

August 11, 2025 08:00 ET – Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October – – VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the